MedTrace Logo

Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14

NCT03404856 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-01-25

No results posted yet for this study

Summary

Study of ORL-1G in Patients With Glycogen Storage Disease Type 14

Conditions

  • Glycogen Storage Disease, Type 14

Interventions

DRUG

ORL-1G - D-galactose

Oral ORL-1G - D-galactose

Sponsors & Collaborators

  • Orpha Labs

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03404856 on ClinicalTrials.gov